The Conversation (0)
STRATA Skin Sciences Announces Licensing Agreement for Certain MelaFind Assets
Jul. 23, 2018 09:46AM PST
Medical Device Investing
STRATA Skin Sciences (NASDAQ:SSKN) has announced a fully paid exclusive and perpetual license agreement related to its discontinued MelaFind device. As quoted in the press release: STRATA retains all intellectual property rights related to the MelaFind device and product line, including patents, design files and PMA approval to market. The strategic entity will be allowed …
STRATA Skin Sciences (NASDAQ:SSKN) has announced a fully paid exclusive and perpetual license agreement related to its discontinued MelaFind device.
As quoted in the press release:
STRATA retains all intellectual property rights related to the MelaFind device and product line, including patents, design files and PMA approval to market. The strategic entity will be allowed exclusive rights to the de-identified digital images.
“We are pleased to come to agreement with this licensing partner for the de-identified images related to the MelaFind device. Rationalizing the MelaFind assets is one step in our ongoing strategic turn-around efforts following our recent financing,” said Dr. Dolev Rafaeli, chief executive officer of STRATA. “While we will look for additional licensing opportunities and continue to evaluate potential M&A opportunities, our main focus is on rebuilding our XTRAC network, expanding internationally and executing on our proven revenue strategy.”
The perpetual license agreement is subject to customary closing conditions.
